Medtronic PLC $MDT Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lessened its stake in Medtronic PLC (NYSE:MDT) by 70.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 393,328 shares of the medical technology company’s stock after selling 929,333 shares during the quarter. HighTower Advisors LLC’s holdings in Medtronic were worth $30,770,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MDT. Anfield Capital Management LLC grew its holdings in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new stake in Medtronic during the 4th quarter worth $27,000. Acumen Wealth Advisors LLC acquired a new position in Medtronic in the 4th quarter worth $29,000. Imprint Wealth LLC acquired a new position in Medtronic in the 3rd quarter worth $31,000. Finally, Basepoint Wealth LLC purchased a new position in Medtronic in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.26% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Evercore set a $105.00 target price on Medtronic in a research report on Monday, July 6th. JPMorgan Chase & Co. reduced their target price on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, August 10th. Finally, Stifel Nicolaus set a $80.00 price target on shares of Medtronic in a research report on Wednesday, June 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.83.

Medtronic Stock Up 2.2%

NYSE:MDT opened at $94.13 on Thursday. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The stock has a 50 day moving average of $83.88 and a 200-day moving average of $86.08. The firm has a market capitalization of $120.49 billion, a PE ratio of 25.24, a price-to-earnings-growth ratio of 2.47 and a beta of 0.55. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter last year, the company earned $1.62 EPS. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts predict that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were issued a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a yield of 3.1%. Medtronic’s dividend payout ratio is presently 77.21%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).